Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Mar;133(Pt 3):771-86.
doi: 10.1093/brain/awq007. Epub 2010 Feb 15.

Multi-system neurological disease is common in patients with OPA1 mutations

Affiliations
Multicenter Study

Multi-system neurological disease is common in patients with OPA1 mutations

P Yu-Wai-Man et al. Brain. 2010 Mar.

Abstract

Additional neurological features have recently been described in seven families transmitting pathogenic mutations in OPA1, the most common cause of autosomal dominant optic atrophy. However, the frequency of these syndromal 'dominant optic atrophy plus' variants and the extent of neurological involvement have not been established. In this large multi-centre study of 104 patients from 45 independent families, including 60 new cases, we show that extra-ocular neurological complications are common in OPA1 disease, and affect up to 20% of all mutational carriers. Bilateral sensorineural deafness beginning in late childhood and early adulthood was a prominent manifestation, followed by a combination of ataxia, myopathy, peripheral neuropathy and progressive external ophthalmoplegia from the third decade of life onwards. We also identified novel clinical presentations with spastic paraparesis mimicking hereditary spastic paraplegia, and a multiple sclerosis-like illness. In contrast to initial reports, multi-system neurological disease was associated with all mutational subtypes, although there was an increased risk with missense mutations [odds ratio = 3.06, 95% confidence interval = 1.44-6.49; P = 0.0027], and mutations located within the guanosine triphosphate-ase region (odds ratio = 2.29, 95% confidence interval = 1.08-4.82; P = 0.0271). Histochemical and molecular characterization of skeletal muscle biopsies revealed the presence of cytochrome c oxidase-deficient fibres and multiple mitochondrial DNA deletions in the majority of patients harbouring OPA1 mutations, even in those with isolated optic nerve involvement. However, the cytochrome c oxidase-deficient load was over four times higher in the dominant optic atrophy + group compared to the pure optic neuropathy group, implicating a causal role for these secondary mitochondrial DNA defects in disease pathophysiology. Individuals with dominant optic atrophy plus phenotypes also had significantly worse visual outcomes, and careful surveillance is therefore mandatory to optimize the detection and management of neurological disability in a group of patients who already have significant visual impairment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagrammatic representation of the OPA1 gene with the location of mutations resulting in DOA+ syndromes. The mutation type is indicated by (i) red stars (missense); (ii) grey squares (nonsense); (iii) blue circles (splice site); and (iv) green triangles (deletion). CC = coiled-coil domain; GE = GTPase effector domain; UTR = untranslated region.
Figure 2
Figure 2
(A) Cumulative distribution curve of age on onset of visual failure in pure DOA and DOA+, and (B) comparison of mean LogMAR visual acuity between patients with pure DOA and DOA+ features (P = 0.0170). The whiskers represent the minimum and maximum LogMAR values, the ends of the boxes are the upper and lower quartiles, the vertical length of the boxes indicate the interquartile range, and the line within the boxes represent the median LogMAR values for each group.
Figure 3
Figure 3
Molecular investigations and MRI neuroimaging of a 58-year-old female presenting with a multiple sclerosis-like illness and harbouring a c.2613 + 1g>a splice-site mutation within intron 25 of the OPA1 gene (UK-6). (A) Family tree of the affected proband (II-3). DNA samples were obtained from her 62-year-old (II-1) and 59-year-old (II-2) brothers, who both had a pure DOA phenotype, and OPA1 sequencing confirmed the presence of the same heterozygous c.2613 + 1g>a variant. The asterisk indicates family members where DNA samples were available for molecular analysis. (B) A 16 kb long-range PCR assay was performed on homogenate DNA extracted from the patients skeletal muscle biopsy, and multiple deletion bands were identified. Lane a: 1 kb DNA ladder with the adjacent numbers indicating the size of the band; lane b: patient; lane c: wild-type control. (C) Axial T2-weighted fluid attenuated inversion recovery and (D) sagittal T2-weighted turbo spin echo slices showing cortical atrophy and characteristic white matter lesions in the periventricular areas and more peripherally near to grey matter.
Figure 4
Figure 4
Mean level of COX-deficiency in skeletal muscle biopsies: (A) pure DOA versus DOA+ phenotypes (P = 0.0226) and (B) pure DOA versus age-matched controls (P < 0.0001). The error bars represent the standard error of the mean.
Figure 5
Figure 5
Clinical, histochemical and molecular features observed in a 59-year-old female with isolated optic nerve involvement due to an exon 27 c.2713C>T (p.R905X) OPA1 missense mutation. (A) Right, and (B) left optic discs displaying generalized pallor of the neuro-retinal rim and pathological excavation. (C) Dual COX-SDH histochemistry performed on 20 µm thick cryostat sections showing the presence of COX-deficient muscle fibres (33/1100, 3.00%). (D) Long-range PCR of the patients homogenate skeletal muscle DNA revealing multiple deletion bands in addition to the wild-type 16-kb fragment. Lane a: 1-kb DNA ladder with the adjacent numbers indicating the size of the band; lane b: patient; lane c: wild-type control.
Figure 6
Figure 6
Comparison of mtDNA copy number in homogenate skeletal muscle DNA from patients with OPA1 mutations (mean = 5144, SD = 2843, n = 24) with age-matched healthy controls (mean = 4669, SD = 2640, n = 20, P = 0.5719), and patients with mtDNA depletion syndromes (mean = 524, SD = 345, n = 6, P = 0.0005). The error bars represent the standard error of the mean.
Figure 7
Figure 7
Evolution of the major clinical features observed in DOA+ syndromes.
Figure 8
Figure 8
In silico prediction of coiled-coil regions within the segment of 37 amino acids encoded by exon 5b: (A) wild-type, and (B) p.S256R substitution. The modelling accuracy increases with larger scanning windows (28 > 21 > 14), and probabilities > 0.5 indicate a high likelihood of coiled-coil conformation. The p.S256R substitution is predicted to reduce the coiled-coil forming potential by ∼45%. (http://www.ch.embnet.org/software/COILS_form.html). Green line = window 14; Blue line = window 21; Red line = window 28.

Comment in

  • Heterozygous OPA1 mutations in Behr syndrome.
    Marelli C, Amati-Bonneau P, Reynier P, Layet V, Layet A, Stevanin G, Brissaud E, Bonneau D, Durr A, Brice A. Marelli C, et al. Brain. 2011 Apr;134(Pt 4):e169; author reply e170. doi: 10.1093/brain/awq306. Epub 2010 Nov 26. Brain. 2011. PMID: 21112924 No abstract available.
  • Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation.
    Pretegiani E, Rufa A, Gallus GN, Cardaioli E, Malandrini A, Federico A. Pretegiani E, et al. Brain. 2011 Nov;134(Pt 11):e195. doi: 10.1093/brain/awr101. Epub 2011 Jun 6. Brain. 2011. PMID: 21646330 No abstract available.
  • Sensorineural hearing loss in OPA1-linked disorders.
    Leruez S, Milea D, Defoort-Dhellemmes S, Colin E, Crochet M, Procaccio V, Ferré M, Lamblin J, Drouin V, Vincent-Delorme C, Lenaers G, Hamel C, Blanchet C, Juul G, Larsen M, Verny C, Reynier P, Amati-Bonneau P, Bonneau D. Leruez S, et al. Brain. 2013 Jul;136(Pt 7):e236. doi: 10.1093/brain/aws340. Epub 2013 Feb 4. Brain. 2013. PMID: 23384603 No abstract available.
  • Reply: Sensorineural hearing loss in OPA1-linked disorders.
    Yu-Wai-Man P, Chinnery PF. Yu-Wai-Man P, et al. Brain. 2013 Jul;136(Pt 7):e237. doi: 10.1093/brain/aws341. Epub 2013 Feb 4. Brain. 2013. PMID: 23650221 Free PMC article. No abstract available.
  • Reply: 'Behr syndrome' with OPA1 compound heterozygote mutations.
    Yu-Wai-Man P, Chinnery PF. Yu-Wai-Man P, et al. Brain. 2015 Jan;138(Pt 1):e322. doi: 10.1093/brain/awu235. Epub 2014 Aug 21. Brain. 2015. PMID: 25146915 Free PMC article. No abstract available.
  • 'Behr syndrome' with OPA1 compound heterozygote mutations.
    Carelli V, Sabatelli M, Carrozzo R, Rizza T, Schimpf S, Wissinger B, Zanna C, Rugolo M, La Morgia C, Caporali L, Carbonelli M, Barboni P, Tonon C, Lodi R, Bertini E. Carelli V, et al. Brain. 2015 Jan;138(Pt 1):e321. doi: 10.1093/brain/awu234. Epub 2014 Aug 21. Brain. 2015. PMID: 25146916 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Alexander C, Votruba M, Pesch UEA, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211–5. - PubMed
    1. Amati-Bonneau P, Guichet A, Olichon A, Chevrollier A, Viala F, Miot S, et al. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Annals of Neurology. 2005;58:958–63. - PubMed
    1. Amati-Bonneau P, Pasquier L, Lainey E, Ferre M, Odent S, Malthiery Y, et al. Sporadic optic atrophy due to synonymous codon change altering mRNA splicing of OPA1. Clin Genet. 2004;67:102–3. - PubMed
    1. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. Brain. 2008;131:338–51. - PubMed
    1. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67:246–51. - PubMed

Publication types

MeSH terms